NYR Share Price Performance
AU$0.30
0.26 (733.33%)
Price AU$0.30
Share PriceAU$0.30
NYR Community Narratives
There are no narratives available yet.
Recent NYR News & Updates
No updates
Nyrada Inc. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.019
- Gross Margin
- -78.58%
- Net Profit Margin
- -241.68%
- Debt/Equity Ratio
- 0%
Nyrada Inc. Competitors
About NYR
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Australian Market Performance
- 7 Days: 1.1%
- 3 Months: 8.3%
- 1 Year: 14.7%
- Year to Date: 7.4%
The market has climbed 1.1% in the last 7 days, lead by the Financials sector with a gain of 1.1%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading